- Expansion of T cells
- Gene transfer by lentiviral or retroviral transduction
Store culture medium at 4°C.
Ai, Y. Q. et al. The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascites. Int. J. Clin. Exp. Med. 7, 4272–81 (2014).
Dodo, K. et al. An efficient large-scale retroviral transduction method involving preloading the vector into a RetroNectin-coated bag with low-temperature shaking. PLoS One 9, e86275 (2014).
Hosoi, H. et al. Stimulation through very late antigen-4 and -5 improves the multifunctionality and memory formation of CD8+ T cells. Eur. J. Immunol. 44, 1747–58 (2014).
Ishikawa, T. et al. Phase I clinical trial of fibronectin CH296-stimulated T cell therapy in patients with advanced cancer. PLoS One 9, e83786 (2014).
Li, W. et al. Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in metastatic brain tumor patients. Oncol. Res. Treat. 38, 160–5 (2015).
Sakamoto, N. et al. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. J. Transl. Med. 13, 277 (2015).
Wang, Y. et al. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo. Exp. Hematol. 41, 241–52.e3 (2013).
Yu, S. S. et al. In vivo persistence of genetically modified T cells generated ex vivo using the fibronectin CH296 stimulation method. Cancer Gene Ther. 15, 508–16 (2008).
Additional Product Information
Please see the product's Certificate of Analysis for information about storage conditions, product components, and technical specifications. Please see the Kit Components List to determine kit components. Certificates of Analysis and Kit Components Lists are located under the Documents tab.